Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

By J. Mann, R. Schmieder, M. McQueen, L. Dyal, H. Schumacher, Janice Pogue, Xingyu Wang, A. Maggioni, A. Budaj, S. Chaithiraphan and 9 more. The Lancet, 2008

1,535 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Nephrology

View Paper: https://www.semanticscholar.org/paper/a1d2b8234ad6ee8b0f36a10b3014735858ff65bc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Philippe van de Borne
2. S. Laurent
3. E. Schiffrin
4. H. S. Boudier
5. B. K. Pedersen
6. B. Saltin

Citations in the corpus

• ESH / ESC Guidelines for the management of arterial hypertension (2013, background): “Lower incidence of CV events and slower progression of renal disease have also been repeatedly associated with treatment-induced reduction in urinary protein excretion in both diabetic and non-diabetic patients,(227,262,535,536,687,688) but, especially for microalbuminuria, discordant results haveal”